Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 62799 | 3.94 |
09:34 ET | 11905 | 3.91 |
09:36 ET | 8197 | 3.9 |
09:38 ET | 77677 | 3.9 |
09:39 ET | 1488 | 3.9 |
09:41 ET | 10239 | 3.875 |
09:43 ET | 66625 | 3.86 |
09:45 ET | 16338 | 3.87 |
09:48 ET | 11899 | 3.875 |
09:50 ET | 55669 | 3.835 |
09:52 ET | 54632 | 3.855 |
09:54 ET | 14326 | 3.85 |
09:56 ET | 18488 | 3.84 |
09:57 ET | 79375 | 3.85 |
09:59 ET | 11504 | 3.84 |
10:01 ET | 34962 | 3.815 |
10:03 ET | 9163 | 3.82 |
10:06 ET | 15795 | 3.8185 |
10:08 ET | 10523 | 3.8014 |
10:10 ET | 5562 | 3.805 |
10:12 ET | 5055 | 3.8 |
10:14 ET | 139656 | 3.82 |
10:15 ET | 11400 | 3.815 |
10:17 ET | 11492 | 3.815 |
10:19 ET | 22420 | 3.7937 |
10:21 ET | 74407 | 3.8 |
10:24 ET | 29914 | 3.79 |
10:26 ET | 6745 | 3.7999 |
10:28 ET | 25740 | 3.795 |
10:30 ET | 347472 | 3.7999 |
10:32 ET | 51934 | 3.8105 |
10:33 ET | 16752 | 3.8 |
10:35 ET | 13319 | 3.825 |
10:37 ET | 6976 | 3.815 |
10:39 ET | 12934 | 3.8012 |
10:42 ET | 3760 | 3.815 |
10:44 ET | 3976 | 3.815 |
10:46 ET | 40638 | 3.835 |
10:48 ET | 1454 | 3.835 |
10:50 ET | 1440 | 3.84 |
10:51 ET | 1632 | 3.835 |
10:53 ET | 17872 | 3.8251 |
10:55 ET | 10483 | 3.825 |
10:57 ET | 1463 | 3.83 |
11:00 ET | 8184 | 3.825 |
11:02 ET | 20166 | 3.82 |
11:04 ET | 25390 | 3.81 |
11:06 ET | 7063 | 3.8 |
11:08 ET | 8600 | 3.805 |
11:09 ET | 1574 | 3.8 |
11:11 ET | 4492 | 3.81 |
11:13 ET | 31076 | 3.8 |
11:15 ET | 2450 | 3.805 |
11:18 ET | 1979 | 3.8088 |
11:20 ET | 7073 | 3.81 |
11:22 ET | 900 | 3.81 |
11:24 ET | 2500 | 3.81 |
11:26 ET | 2190 | 3.81 |
11:27 ET | 1860 | 3.81 |
11:29 ET | 1800 | 3.81 |
11:31 ET | 700 | 3.81 |
11:33 ET | 39411 | 3.8 |
11:36 ET | 2386 | 3.805 |
11:38 ET | 5720 | 3.81 |
11:40 ET | 622 | 3.805 |
11:42 ET | 9331 | 3.815 |
11:44 ET | 14813 | 3.805 |
11:45 ET | 1193 | 3.805 |
11:47 ET | 1602 | 3.8 |
11:49 ET | 30483 | 3.8 |
11:51 ET | 7159 | 3.8 |
11:54 ET | 8163 | 3.8102 |
11:56 ET | 47826 | 3.8201 |
11:58 ET | 6753 | 3.81 |
12:00 ET | 932 | 3.815 |
12:02 ET | 7979 | 3.805 |
12:03 ET | 1789 | 3.8 |
12:05 ET | 34614 | 3.8 |
12:07 ET | 2084 | 3.8 |
12:09 ET | 3410 | 3.8 |
12:12 ET | 18507 | 3.795 |
12:14 ET | 45723 | 3.785 |
12:16 ET | 29227 | 3.8 |
12:18 ET | 11435 | 3.795 |
12:20 ET | 10285 | 3.785 |
12:21 ET | 16004 | 3.785 |
12:23 ET | 2061 | 3.785 |
12:25 ET | 34000 | 3.785 |
12:27 ET | 54018 | 3.765 |
12:30 ET | 35027 | 3.765 |
12:32 ET | 9537 | 3.765 |
12:34 ET | 6105 | 3.76 |
12:36 ET | 24564 | 3.765 |
12:38 ET | 9968 | 3.765 |
12:39 ET | 25238 | 3.775 |
12:41 ET | 3050 | 3.78 |
12:43 ET | 2000 | 3.78 |
12:45 ET | 15043 | 3.785 |
12:48 ET | 19046 | 3.79 |
12:50 ET | 16179 | 3.8 |
12:52 ET | 3724 | 3.795 |
12:54 ET | 17919 | 3.805 |
12:56 ET | 20916 | 3.8067 |
12:57 ET | 6574 | 3.81 |
12:59 ET | 700 | 3.81 |
01:01 ET | 2739 | 3.8012 |
01:03 ET | 20453 | 3.8 |
01:06 ET | 300 | 3.795 |
01:08 ET | 7475 | 3.805 |
01:10 ET | 18165 | 3.8 |
01:12 ET | 7714 | 3.795 |
01:14 ET | 2200 | 3.8 |
01:15 ET | 3371 | 3.795 |
01:17 ET | 43039 | 3.78 |
01:19 ET | 4717 | 3.775 |
01:21 ET | 17978 | 3.765 |
01:24 ET | 22030 | 3.775 |
01:26 ET | 69998 | 3.795 |
01:28 ET | 4172 | 3.795 |
01:30 ET | 2770 | 3.8 |
01:32 ET | 6342 | 3.795 |
01:33 ET | 2447 | 3.8 |
01:35 ET | 5261 | 3.795 |
01:37 ET | 2100 | 3.8 |
01:39 ET | 600 | 3.8 |
01:42 ET | 12247 | 3.795 |
01:44 ET | 4581 | 3.795 |
01:46 ET | 9296 | 3.806 |
01:48 ET | 2200 | 3.81 |
01:50 ET | 3436 | 3.81 |
01:51 ET | 4834 | 3.805 |
01:53 ET | 2766 | 3.81 |
01:55 ET | 2328 | 3.81 |
01:57 ET | 5797 | 3.805 |
02:00 ET | 3041 | 3.805 |
02:02 ET | 22085 | 3.8 |
02:04 ET | 4476 | 3.795 |
02:06 ET | 4514 | 3.7925 |
02:08 ET | 13671 | 3.81 |
02:09 ET | 21738 | 3.81 |
02:11 ET | 3777 | 3.81 |
02:13 ET | 4234 | 3.805 |
02:15 ET | 1921 | 3.805 |
02:18 ET | 3600 | 3.81 |
02:20 ET | 2808 | 3.81 |
02:22 ET | 1300 | 3.81 |
02:24 ET | 2686 | 3.81 |
02:26 ET | 3115 | 3.81 |
02:27 ET | 7767 | 3.805 |
02:29 ET | 4525 | 3.805 |
02:31 ET | 25376 | 3.8 |
02:33 ET | 21121 | 3.795 |
02:36 ET | 11660 | 3.8 |
02:38 ET | 2254 | 3.795 |
02:40 ET | 35138 | 3.82 |
02:42 ET | 1989 | 3.82 |
02:44 ET | 1700 | 3.82 |
02:45 ET | 4918 | 3.82 |
02:47 ET | 2650 | 3.815 |
02:49 ET | 1823 | 3.82 |
02:51 ET | 18416 | 3.8 |
02:54 ET | 29638 | 3.795 |
02:56 ET | 3691 | 3.8 |
02:58 ET | 49562 | 3.8 |
03:00 ET | 7514 | 3.805 |
03:02 ET | 7756 | 3.81 |
03:03 ET | 2891 | 3.81 |
03:05 ET | 2864 | 3.805 |
03:07 ET | 12521 | 3.8014 |
03:09 ET | 2917 | 3.81 |
03:12 ET | 33657 | 3.7925 |
03:14 ET | 33961 | 3.805 |
03:16 ET | 996 | 3.805 |
03:18 ET | 6111 | 3.81 |
03:20 ET | 6600 | 3.81 |
03:21 ET | 28668 | 3.8 |
03:23 ET | 2968 | 3.8 |
03:25 ET | 7733 | 3.805 |
03:27 ET | 2500 | 3.8 |
03:30 ET | 11277 | 3.805 |
03:32 ET | 33526 | 3.82 |
03:34 ET | 2888 | 3.82 |
03:36 ET | 2991 | 3.815 |
03:38 ET | 2834 | 3.82 |
03:39 ET | 10543 | 3.815 |
03:41 ET | 3716 | 3.82 |
03:43 ET | 10304 | 3.81 |
03:45 ET | 12994 | 3.815 |
03:48 ET | 8621 | 3.82 |
03:50 ET | 15887 | 3.82 |
03:52 ET | 73044 | 3.805 |
03:54 ET | 19011 | 3.815 |
03:56 ET | 110263 | 3.8 |
03:57 ET | 43675 | 3.81 |
03:59 ET | 98376 | 3.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.3B | -11.0x | --- |
Vera Therapeutics Inc | 2.2B | -20.2x | --- |
Dyne Therapeutics Inc | 2.3B | -6.6x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -7.9x | --- |
Avidity Biosciences Inc | 2.5B | -8.8x | --- |
Keros Therapeutics Inc | 2.0B | -10.6x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -11.0x |
Price/Sales (TTM) | 4,334.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.